Sg3 Management, LLC Aurinia Pharmaceuticals Inc. Call Options Transaction History

Sg3 Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$5.94 - $11.27 $53,460 - $101,430	-9,000 Closed	0 $0
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $1.46 Million - $2.08 Million	-162,800 Reduced 94.76%	9,000 $90,000
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $110,550 - $247,280	-11,000 Reduced 6.02%	171,800 $2.13 Million
Q4 2021 Feb 15, 2022	BUY	$17.78 - $33.08 $1.77 Million - $3.3 Million	99,800 Added 120.24%	182,800 $4.18 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $808,820 - $1.74 Million	74,000 Added 822.22%	83,000 $1.84 Million
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $1.87 Million - $2.72 Million	-187,000 Reduced 95.41%	9,000 $117,000
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $2.08 Million - $3.17 Million	-169,500 Reduced 46.37%	196,000 $2.55 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $3.05 Million - $3.78 Million	235,500 Added 181.15%	365,500 $5.06 Million
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $1.71 Million - $2.16 Million	129,900 Added 129900.0%	130,000 $1.92 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $1,412 - $1,832	100 New	100 $2,000

227

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.